isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancy
Conditions
Hematological Malignancy
Trial Timeline
Oct 2, 2017 → Jul 5, 2019
NCT ID
NCT03241550About isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oral is a phase 1 stage product being developed by Astellas Pharma for Hematological Malignancy. The current trial status is completed. This product is registered under clinical trial identifier NCT03241550. Target conditions include Hematological Malignancy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03241550 | Phase 1 | Completed |
Competing Products
20 competing products in Hematological Malignancy